Project Grant RC2DK144787
Award Date 9/25/25
Completion Date 7/31/30
Dollars Obligated $1.7M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- This $681,562 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate approaches for enhancing the metabolic maturity and functionality of human pluripotent stem cell-derived islet organoids, with the goal of improving their survival and efficacy for transplantation as a treatment for type 1 diabetes. The research will examine the use of pharmacological agents...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,999 to the University of Florida to develop innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. The goal is to evaluate these novel heparanase inhibitors in murine models as a...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) provides $138,753 to The Washington University to support research on cytoskeletal regulation of gut tube organogenesis and subsequent maturation of stem cell-derived islets. The goal is to enable a cell-based therapy to become a viable and widely-used treatment option for type 1 diabetes, which results from the autoimmune destruction of insulin-producing beta cells. The research will...
- This $3,140,632 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research program) aims to elucidate the mechanisms underlying human endocrine lineage commitment and harness this knowledge to improve strategies for beta cell replacement in diabetes treatment. The 4-year project, awarded to the Regents of the University of California, San Francisco, seeks to enhance the...
- This $2,263,983 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to develop "engineered regulatory T cells (Tregs)" as an immunotherapy for type 1 diabetes. The central goal is to create antigen-specific Tregs that can more effectively suppress the autoimmune destruction of insulin-producing beta cells. The research...
- This federal Project Grant award of $208,428, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research), aims to enhance the safety and efficacy of stem cell-derived islet transplantation for treating type 1 diabetes. The key objectives are to improve the survival and engraftment of the transplanted cells, enable long-term insulin independence, and develop safety mechanisms to retrieve the graft...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $132,270 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Florida. The grant aims to develop a multi-functional 3D-printed biomaterial scaffold that improves the vascularization, engraftment, and immunoprotection of transplanted pancreatic islets for the treatment of type 1 diabetes. The project has two key objectives: 1) Identify...
- This $372,067 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of an immune evasive stem cell line for type 1 diabetes regenerative therapy. The grant recipient, Aleutian Therapeutics, Inc., a biotechnology company in Los Angeles, California, is conducting research to create gene editing technologies that enable allogeneic...
- The University of California, Davis received a $126,480 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to conduct research on the role of the signaling protein 14-3-3-z in regulating the crosstalk between pancreatic islet cells. The research aims to define a new pathway regulating 14-3-3-z expression in beta cells and investigate how this impacts alpha cell function and glucose-stimulated insulin secretion. This project is expected...
- The University of Chicago was awarded a $249,000 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research program) with a project period from May 1, 2025 to April 30, 2028. The grant will fund research to characterize the m6A methylome of aging B-cells and identify m6A-regulated pathways underlying accelerated B-cell senescence in diabetes. The overarching goal is to determine if m6A is a...